You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLabetalol
Accession NumberDB00598  (APRD01062)
TypeSmall Molecule
GroupsApproved
DescriptionBlocker of both alpha- and beta-adrenergic receptors that is used as an antihypertensive. [PubChem]
Structure
Thumb
Synonyms
3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol
5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide
Labetalol
Labetalolum
Labetolol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Labetalol Hydrochloridetablet200 mg/1oralCounty Line Pharmaceuticals LLC2014-12-01Not applicableUs
Labetalol Hydrochloridetablet300 mg/1oralCounty Line Pharmaceuticals LLC2014-12-01Not applicableUs
Labetalol Hydrochloridetablet100 mg/1oralCounty Line Pharmaceuticals LLC2014-12-01Not applicableUs
Labetalol Hydrochloride Injectionsolution5 mgintravenousOmega Laboratories LtdNot applicableNot applicableCanada
Labetalol Hydrochloride Injection USPliquid5 mgintravenousSandoz Canada Incorporated1998-03-17Not applicableCanada
Labetalol Hydrochloride Injection USPsolution5 mgintravenousHospira Healthcare Corporation2015-06-02Not applicableCanada
Labetalol Hydrochloride Injection, USPsolution5 mgintravenousMylan Pharmaceuticals Ulc2012-08-29Not applicableCanada
Labetolol Hydrochloride Injection USPsolution5 mgintravenousSterimax IncNot applicableNot applicableCanada
Mylan-labetalol Hydrochloride Injection, USPsolution5 mgintravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Trandatetablet100 mg/1oralPrometheus Laboratories Inc.1984-05-31Not applicableUs
Trandatetablet200 mgoralPaladin Labs Inc1997-04-01Not applicableCanada
Trandatetablet200 mg/1oralPrometheus Laboratories Inc.1984-05-31Not applicableUs
Trandatetablet300 mg/1oralPrometheus Laboratories Inc.1984-05-31Not applicableUs
Trandatetablet100 mgoralPaladin Labs Inc1996-07-30Not applicableCanada
Trandate 5mg/mlliquid5 mgintravenousShire Biochem Inc1996-08-232003-10-16Canada
Trandate Inj 5mg/mlliquid5 mgintravenousGlaxo Canada Inc1986-12-311996-09-10Canada
Trandate Tab 100mgtablet100 mgoralGlaxo Canada Inc1984-12-311996-09-10Canada
Trandate Tab 200mgtablet200 mgoralGlaxo Canada Inc1984-12-311998-07-31Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-labetalol Tabletstablet100 mgoralApotex Inc2001-03-16Not applicableCanada
Apo-labetalol Tabletstablet200 mgoralApotex Inc2001-06-01Not applicableCanada
Labetaloltablet, film coated300 mg/1oralSun Pharmaceutical Industries, Inc.1999-07-29Not applicableUs
Labetalolinjection5 mg/mLintravenousSagent Pharmaceuticals2010-02-17Not applicableUs
Labetaloltablet, film coated100 mg/1oralSun Pharmaceutical Industries, Inc.1999-07-29Not applicableUs
Labetaloltablet, film coated200 mg/1oralSun Pharmaceutical Industries, Inc.1999-07-29Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralMylan Institutional Inc.2000-01-15Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralPar Pharmaceutical Inc.2012-07-24Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralCardinal Health2011-05-06Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralEon Labs, Inc.1998-08-04Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralREMEDYREPACK INC.2013-10-29Not applicableUs
Labetalol HCltablet, film coated300 mg/1oralCardinal Health1998-08-04Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralAmerican Health Packaging2015-06-01Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralMylan Institutional Inc.2000-01-15Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralPar Pharmaceutical Inc.2012-07-24Not applicableUs
Labetalol HCltablet, film coated300 mg/1oralEon Labs, Inc.1998-08-04Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralAmerican Health Packaging2015-06-01Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2006-11-15Not applicableUs
Labetalol HCltablet, film coated300 mg/1oralPar Pharmaceutical Inc.2012-07-24Not applicableUs
Labetalol HCltablet, film coated300 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralCardinal Health2011-05-06Not applicableUs
Labetalol HCltablet, film coated300 mg/1oralAmerican Health Packaging2015-06-01Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralEon Labs, Inc.1998-08-04Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralREMEDYREPACK INC.2013-06-03Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralREMEDYREPACK INC.2016-02-23Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralREMEDYREPACK INC.2015-10-20Not applicableUs
Labetalol Hydrochlorideinjection, solution5 mg/mLintravenousGland Pharma Limited2012-04-19Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralPhysicians Total Care, Inc.2004-05-06Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralGolden State Medical Supply, Inc.2013-04-16Not applicableUs
Labetalol Hydrochlorideinjection, solution5 mg/mLintravenousHospira, Inc.1999-11-29Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralRebel Distributors Corp1998-08-03Not applicableUs
Labetalol Hydrochloridetablet100 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralbryant ranch prepack1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralCardinal Health2011-01-01Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralIVAX Pharmaceuticals, Inc.1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-14Not applicableUs
Labetalol Hydrochloridetablet300 mg/1oralREMEDYREPACK INC.2011-06-20Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralMc Kesson Contract Packaging2012-03-21Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralSt Marys Medical Park Pharmacy2014-01-30Not applicableUs
Labetalol Hydrochlorideinjection, solution5 mg/mLintravenousAkorn, Inc.2004-09-01Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralAmerican Health Packaging2011-03-08Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralWatson Laboratories, Inc.1998-08-03Not applicableUs
Labetalol Hydrochloridetablet200 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralbryant ranch prepack1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralCardinal Health2011-01-01Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralIVAX Pharmaceuticals, Inc.1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-01Not applicableUs
Labetalol Hydrochloridetablet200 mg/1oralREMEDYREPACK INC.2011-09-27Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralAmerican Health Packaging2011-03-082015-12-01Us
Labetalol Hydrochloridetablet200 mg/1oralCardinal Health2009-06-10Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralSt Marys Medical Park Pharmacy2014-01-30Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralRebel Distributors Corp1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralPhysicians Total Care, Inc.2003-08-19Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralGolden State Medical Supply, Inc.2013-04-16Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralWatson Laboratories, Inc.1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralLake Erie Medical DBA Quality Care Products LLC1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralAmerican Health Packaging2011-03-08Not applicableUs
Labetalol Hydrochlorideinjection, solution5 mg/mLintravenousCardinal Health1999-11-29Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralIVAX Pharmaceuticals, Inc.1998-08-03Not applicableUs
Labetalol Hydrochloridetablet300 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralREMEDYREPACK INC.2013-06-04Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-01Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralUnit Dose Services1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralCardinal Health2011-03-08Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralREMEDYREPACK INC.2015-08-13Not applicableUs
Labetalol Hydrochlorideinjection, solution5 mg/mLintravenousHospira, Inc.1999-11-29Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralRebel Distributors Corp1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralPhysicians Total Care, Inc.2004-08-25Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralGolden State Medical Supply, Inc.2013-04-16Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralWatson Laboratories, Inc.1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralREMEDYREPACK INC.2010-11-30Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralDispensing Solutions, Inc.2011-01-01Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralSTAT Rx USA LLC1998-08-03Not applicableUs
Labetalol Hydrochlorideinjection, solution5 mg/mLintravenousMylan Institutional LLC2012-06-29Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-01Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralUnit Dose Services1998-08-03Not applicableUs
Labetalol Hydrochloridetablet100 mg/1oralCardinal Health2009-06-10Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Labetalol HClinjection, solution5 mg/mLintravenousCantrell Drug Company2012-02-23Not applicableUs
International Brands
NameCompany
AlbetolLeiras
LatolStandard
NormadateGlaxoSmithKline
NormodyneSchering
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Labetalol Hydrochloride
Thumb
  • InChI Key: WQVZLXWQESQGIF-UHFFFAOYNA-N
  • Monoisotopic Mass: 364.155370383
  • Average Mass: 364.866
DBSALT000320
Categories
UNIIR5H8897N95
CAS number36894-69-6
WeightAverage: 328.4055
Monoisotopic: 328.178692644
Chemical FormulaC19H24N2O3
InChI KeyInChIKey=SGUAFYQXFOLMHL-UHFFFAOYSA-N
InChI
InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)
IUPAC Name
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
SMILES
CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentSalicylamides
Alternative Parents
Substituents
  • Salicylamide
  • Phenylpropylamine
  • Benzamide
  • Benzoyl
  • Aralkylamine
  • Phenol
  • Vinylogous acid
  • Secondary alcohol
  • Primary carboxylic acid amide
  • Carboxamide group
  • 1,2-aminoalcohol
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the management of hypertension (alone or in combination with other classes of antihypertensive agents), as well as chronic stable angina pectoris and sympathetic overactivity syndrome associated with severe tetanus. Labetalol is used parenterally for immediate reduction in blood pressure in severe hypertension or in hypertensive crises when considered an emergency, for the control of blood pressure in patients with pheochromocytoma and pregnant women with preeclampsia, and to produce controlled hypotension during anesthesia to reduce bleeding resulting from surgical procedures.
PharmacodynamicsLabetalol is an selective alpha-1 and non-selective beta adrenergic blocker used to treat high blood pressure. It works by blocking these adrenergic receptors, which slows sinus heart rate, decreases peripheral vascular resistance, and decreases cardiac output. Labetalol has two asymmetric centers and therefore, exists as a molecular complex of two diastereoisomeric pairs. Dilevalol, the R,R' stereoisomer, makes up 25% of racemic labetalol.
Mechanism of actionLabetalol HCl combines both selective, competitive, alpha-1-adrenergic blocking and nonselective, competitive, beta-adrenergic blocking activity in a single substance. In man, the ratios of alpha- to beta- blockade have been estimated to be approximately 1:3 and 1:7 following oral and intravenous (IV) administration, respectively. The principal physiologic action of labetalol is to competitively block adrenergic stimulation of β-receptors within the myocardium (β1-receptors) and within bronchial and vascular smooth muscle (β2-receptors), and α1-receptors within vascular smooth muscle. This causes a decrease in systemic arterial blood pressure and systemic vascular resistance without a substantial reduction in resting heart rate, cardiac output, or stroke volume, apparently because of its combined α- and β-adrenergic blocking activity.
Related Articles
AbsorptionCompletely absorbed (100%) from the gastrointestinal tract with peak plasma levels occurring 1 to 2 hours after oral administration. The absolute bioavailability of labetalol is increased when administered with food.
Volume of distributionNot Available
Protein binding50%
Metabolism

Primarily hepatic, undergoes significant first pass metabolism

Route of eliminationThese metabolites are present in plasma and are excreted in the urine, and via the bile, into the feces.
Half life6-8 hours
ClearanceNot Available
ToxicityLD50 = 66 mg/kg (Rat, IV). Side effects or adverse reactions include dizziness when standing up, very low blood pressure, severely slow heartbeat, weakness, diminished sexual function, fatigue
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Labetalol Action PathwayDrug actionSMP00368
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9943
Blood Brain Barrier-0.8313
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7073
P-glycoprotein inhibitor INon-inhibitor0.8908
P-glycoprotein inhibitor IINon-inhibitor0.9269
Renal organic cation transporterNon-inhibitor0.8457
CYP450 2C9 substrateNon-substrate0.7448
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6202
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8995
CYP450 3A4 inhibitorNon-inhibitor0.8256
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8383
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9189
BiodegradationNot ready biodegradable0.945
Rat acute toxicity2.1174 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9501
hERG inhibition (predictor II)Non-inhibitor0.7398
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apothecon inc div bristol myers squibb
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Taylor pharmaceuticals
  • Sagent strides llc
  • Schering corp sub schering plough corp
  • Prometheus laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Injectionintravenous5 mg/mL
Injection, solutionintravenous5 mg/mL
Tabletoral100 mg/1
Tabletoral200 mg/1
Tabletoral300 mg/1
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral200 mg/1
Tablet, film coatedoral300 mg/1
Liquidintravenous5 mg
Solutionintravenous5 mg
Tabletoral100 mg
Tabletoral200 mg
Prices
Unit descriptionCostUnit
Labetalol Hydrochloride 5 mg/ml1.36USD ml
Trandate 300 mg tablet1.28USD tablet
Trandate 5 mg/ml vial1.25USD ml
Trandate 200 mg tablet1.08USD tablet
Labetalol hcl 300 mg tablet1.02USD tablet
Normodyne 200 mg tablet1.0USD tablet
Labetalol hcl 200 mg tablet0.76USD tablet
Trandate 100 mg tablet0.68USD tablet
Labetalol hcl 100 mg tablet0.53USD tablet
Trandate 200 mg Tablet0.47USD tablet
Trandate 100 mg Tablet0.27USD tablet
Labetalol hcl 5 mg/ml vial0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point188 °CU.S. Patent 4,012,444.
water solubility117 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP3.09HANSCH,C ET AL. (1995)
Caco2 permeability-5.03ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00578 mg/mLALOGPS
logP1.73ALOGPS
logP1.89ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)8.05ChemAxon
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area95.58 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity94.72 m3·mol-1ChemAxon
Polarizability36.83 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-03dl-7900000000-e18d52bcb93357c4a7e2View in MoNA
References
Synthesis Reference

U.S. Patent 4,012,444.

General ReferencesNot Available
External Links
ATC CodesC07BG01C07CG01C07AG01
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelDownload (401 KB)
MSDSDownload (53.7 KB)
Interactions
Drug Interactions
Drug
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Labetalol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Labetalol.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Labetalol.
AbirateroneThe metabolism of Labetalol can be decreased when combined with Abiraterone.
AcebutololLabetalol may increase the hypotensive activities of Acebutolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Labetalol.
AcepromazineAcepromazine may increase the hypotensive activities of Labetalol.
AcetazolamideThe risk or severity of adverse effects can be increased when Labetalol is combined with Acetazolamide.
AcetohexamideLabetalol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Labetalol is combined with Acetylcholine.
AcetyldigitoxinLabetalol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Labetalol.
AdapaleneAdapalene may decrease the antihypertensive activities of Labetalol.
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Labetalol.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Labetalol.
AlfuzosinAlfuzosin may increase the antihypertensive activities of Labetalol.
AlimemazineAlimemazine may increase the hypotensive activities of Labetalol.
AliskirenLabetalol may increase the hypotensive activities of Aliskiren.
AlprenololLabetalol may increase the hypotensive activities of Alprenolol.
AmbenoniumAmbenonium may increase the bradycardic activities of Labetalol.
AmbrisentanLabetalol may increase the hypotensive activities of Ambrisentan.
AmifostineLabetalol may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Labetalol.
AmiodaroneAmiodarone may increase the bradycardic activities of Labetalol.
AmlodipineAmlodipine may increase the hypotensive activities of Labetalol.
AmobarbitalAmobarbital may increase the hypotensive activities of Labetalol.
AmodiaquineThe metabolism of Labetalol can be decreased when combined with Amodiaquine.
AmoxapineThe serum concentration of Labetalol can be increased when it is combined with Amoxapine.
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Labetalol.
AmrinoneLabetalol may increase the hypotensive activities of Amrinone.
Amyl NitriteThe risk or severity of adverse effects can be increased when Labetalol is combined with Amyl Nitrite.
AntipyrineAntipyrine may decrease the antihypertensive activities of Labetalol.
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Labetalol.
ApraclonidineThe risk or severity of adverse effects can be increased when Labetalol is combined with Apraclonidine.
ApremilastApremilast may decrease the antihypertensive activities of Labetalol.
ArecolineThe risk or severity of adverse effects can be increased when Labetalol is combined with Arecoline.
AripiprazoleAripiprazole may increase the hypotensive activities of Labetalol.
ArotinololArotinolol may increase the orthostatic hypotensive activities of Labetalol.
ArtemetherThe metabolism of Labetalol can be decreased when combined with Artemether.
AtenololAtenolol may increase the hypotensive activities of Labetalol.
AtomoxetineAtomoxetine may increase the hypertensive activities of Labetalol.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Labetalol.
AzelastineAzelastine may decrease the antihypertensive activities of Labetalol.
AzelnidipineLabetalol may increase the hypotensive activities of Azelnidipine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Labetalol is combined with Azilsartan medoxomil.
AzimilideLabetalol may increase the hypotensive activities of Azimilide.
BalsalazideBalsalazide may decrease the antihypertensive activities of Labetalol.
BarbitalBarbital may increase the hypotensive activities of Labetalol.
BarnidipineLabetalol may increase the hypotensive activities of Barnidipine.
BefunololBefunolol may increase the orthostatic hypotensive activities of Labetalol.
BenazeprilBenazepril may increase the hypotensive activities of Labetalol.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Labetalol.
BenidipineLabetalol may increase the hypotensive activities of Benidipine.
BenmoxinBenmoxin may increase the hypotensive activities of Labetalol.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Labetalol.
BenzphetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Benzphetamine.
BepridilLabetalol may increase the hypotensive activities of Bepridil.
BeractantLabetalol may increase the bradycardic activities of Beractant.
BetaxololBetaxolol may increase the hypotensive activities of Labetalol.
BethanecholThe risk or severity of adverse effects can be increased when Labetalol is combined with Bethanechol.
BethanidineBethanidine may increase the hypotensive activities of Labetalol.
BevantololBevantolol may increase the orthostatic hypotensive activities of Labetalol.
BimatoprostLabetalol may increase the hypotensive activities of Bimatoprost.
BisoprololLabetalol may increase the hypotensive activities of Bisoprolol.
BopindololBopindolol may increase the orthostatic hypotensive activities of Labetalol.
BosentanBosentan may increase the hypotensive activities of Labetalol.
BretyliumBretylium may increase the bradycardic activities of Labetalol.
BretyliumLabetalol may increase the hypotensive activities of Bretylium.
BrimonidineLabetalol may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Labetalol.
BromfenacBromfenac may decrease the antihypertensive activities of Labetalol.
BromocriptineLabetalol may increase the vasoconstricting activities of Bromocriptine.
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Labetalol.
BufuralolBufuralol may increase the orthostatic hypotensive activities of Labetalol.
BumetanideThe risk or severity of adverse effects can be increased when Labetalol is combined with Bumetanide.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Labetalol.
BupranololLabetalol may increase the hypotensive activities of Bupranolol.
BupropionThe metabolism of Labetalol can be decreased when combined with Bupropion.
CabergolineLabetalol may increase the vasoconstricting activities of Cabergoline.
CalfactantLabetalol may increase the bradycardic activities of Calfactant.
CanagliflozinThe risk or severity of adverse effects can be increased when Labetalol is combined with Canagliflozin.
CandesartanLabetalol may increase the hypotensive activities of Candesartan.
CandoxatrilLabetalol may increase the hypotensive activities of Candoxatril.
CaptoprilLabetalol may increase the hypotensive activities of Captopril.
CarbacholThe risk or severity of adverse effects can be increased when Labetalol is combined with Carbachol.
CaroxazoneCaroxazone may increase the hypotensive activities of Labetalol.
CarprofenCarprofen may decrease the antihypertensive activities of Labetalol.
CarteololCarteolol may increase the hypotensive activities of Labetalol.
CarvedilolLabetalol may increase the antihypertensive activities of Carvedilol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Labetalol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Labetalol.
CeliprololLabetalol may increase the hypotensive activities of Celiprolol.
CeritinibLabetalol may increase the bradycardic activities of Ceritinib.
CevimelineThe risk or severity of adverse effects can be increased when Labetalol is combined with Cevimeline.
ChloroquineChloroquine may decrease the antihypertensive activities of Labetalol.
ChlorothiazideLabetalol may increase the hypotensive activities of Chlorothiazide.
ChlorphentermineThe risk or severity of adverse effects can be increased when Labetalol is combined with Chlorphentermine.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Labetalol.
ChlorpropamideLabetalol may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Labetalol.
CholecalciferolThe metabolism of Labetalol can be decreased when combined with Cholecalciferol.
CilazaprilLabetalol may increase the hypotensive activities of Cilazapril.
CilnidipineLabetalol may increase the hypotensive activities of Cilnidipine.
CimetidineThe metabolism of Labetalol can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Labetalol can be decreased when combined with Cinacalcet.
CinnarizineLabetalol may increase the hypotensive activities of Cinnarizine.
CirazolineLabetalol may decrease the vasoconstricting activities of Cirazoline.
CitalopramThe metabolism of Labetalol can be decreased when combined with Citalopram.
ClemastineThe metabolism of Labetalol can be decreased when combined with Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Labetalol is combined with Clenbuterol.
ClevidipineLabetalol may increase the hypotensive activities of Clevidipine.
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Labetalol.
ClobazamThe metabolism of Labetalol can be decreased when combined with Clobazam.
ClomipramineThe serum concentration of Labetalol can be increased when it is combined with Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Labetalol.
ClonixinClonixin may decrease the antihypertensive activities of Labetalol.
ClotrimazoleThe metabolism of Labetalol can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Labetalol can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Labetalol can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Labetalol can be decreased when combined with Cocaine.
CoumaphosCoumaphos may increase the bradycardic activities of Labetalol.
CrizotinibLabetalol may increase the bradycardic activities of Crizotinib.
CryptenamineLabetalol may increase the hypotensive activities of Cryptenamine.
CyclothiazideLabetalol may increase the hypotensive activities of Cyclothiazide.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Labetalol.
DapagliflozinThe risk or severity of adverse effects can be increased when Labetalol is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Labetalol.
DarifenacinThe metabolism of Labetalol can be decreased when combined with Darifenacin.
DarodipineLabetalol may increase the hypotensive activities of Darodipine.
DarunavirThe serum concentration of Labetalol can be increased when it is combined with Darunavir.
DebrisoquinLabetalol may increase the hypotensive activities of Debrisoquin.
DecamethoniumDecamethonium may increase the bradycardic activities of Labetalol.
DelavirdineThe metabolism of Labetalol can be decreased when combined with Delavirdine.
DemecariumDemecarium may increase the bradycardic activities of Labetalol.
DeserpidineLabetalol may increase the hypotensive activities of Deserpidine.
DesipramineThe metabolism of Labetalol can be decreased when combined with Desipramine.
DeslanosideLabetalol may increase the bradycardic activities of Deslanoside.
DexmedetomidineThe risk or severity of adverse effects can be increased when Labetalol is combined with Dexmedetomidine.
DiazoxideDiazoxide may increase the hypotensive activities of Labetalol.
DichlorvosDichlorvos may increase the bradycardic activities of Labetalol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Labetalol.
DiclofenamideThe risk or severity of adverse effects can be increased when Labetalol is combined with Diclofenamide.
DiflunisalDiflunisal may decrease the antihypertensive activities of Labetalol.
DigitoxinLabetalol may increase the bradycardic activities of Digitoxin.
DigoxinLabetalol may increase the bradycardic activities of Digoxin.
DihydroergotamineLabetalol may increase the vasoconstricting activities of Dihydroergotamine.
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Labetalol.
DiltiazemDiltiazem may increase the hypotensive activities of Labetalol.
DinutuximabThe risk or severity of adverse effects can be increased when Labetalol is combined with Dinutuximab.
DiphenhydramineThe metabolism of Labetalol can be decreased when combined with Diphenhydramine.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Labetalol.
DipyridamoleDipyridamole may increase the bradycardic activities of Labetalol.
DipyridamoleThe risk or severity of adverse effects can be increased when Labetalol is combined with Dipyridamole.
DisopyramideDisopyramide may increase the bradycardic activities of Labetalol.
DobutamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Dobutamine.
DonepezilDonepezil may increase the bradycardic activities of Labetalol.
DopamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Dopamine.
DorzolamideLabetalol may increase the hypotensive activities of Dorzolamide.
DotarizineLabetalol may increase the hypotensive activities of Dotarizine.
DoxazosinDoxazosin may increase the antihypertensive activities of Labetalol.
DoxofyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Doxofylline.
DronabinolDronabinol may increase the tachycardic activities of Labetalol.
DronedaroneLabetalol may increase the bradycardic activities of Dronedarone.
DroxicamDroxicam may decrease the antihypertensive activities of Labetalol.
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Labetalol.
DuloxetineLabetalol may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineThe metabolism of Labetalol can be decreased when combined with Duloxetine.
EchothiophateEchothiophate may increase the bradycardic activities of Labetalol.
EdrophoniumEdrophonium may increase the bradycardic activities of Labetalol.
EfonidipineLabetalol may increase the hypotensive activities of Efonidipine.
EliglustatThe metabolism of Labetalol can be decreased when combined with Eliglustat.
EmpagliflozinThe risk or severity of adverse effects can be increased when Labetalol is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Labetalol.
EnalaprilatLabetalol may increase the hypotensive activities of Enalaprilat.
EperisoneLabetalol may increase the hypotensive activities of Eperisone.
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Labetalol.
EphedrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Ephedrine.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Labetalol is combined with EPIBATIDINE.
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Labetalol.
EpirizoleEpirizole may decrease the antihypertensive activities of Labetalol.
EplerenoneThe risk or severity of adverse effects can be increased when Labetalol is combined with Eplerenone.
EpoprostenolLabetalol may increase the hypotensive activities of Epoprostenol.
EprosartanLabetalol may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateLabetalol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovineLabetalol may increase the vasoconstricting activities of Ergonovine.
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Labetalol.
ErgotamineLabetalol may decrease the vasoconstricting activities of Ergotamine.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Labetalol.
Etacrynic acidThe risk or severity of adverse effects can be increased when Labetalol is combined with Etacrynic acid.
EtanerceptEtanercept may decrease the antihypertensive activities of Labetalol.
EtilefrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Etilefrine.
EtodolacEtodolac may decrease the antihypertensive activities of Labetalol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Labetalol.
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Labetalol.
EtoperidoneThe serum concentration of Labetalol can be increased when it is combined with Etoperidone.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Labetalol.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Labetalol.
exisulindexisulind may decrease the antihypertensive activities of Labetalol.
FelodipineLabetalol may increase the hypotensive activities of Felodipine.
FenbufenFenbufen may decrease the antihypertensive activities of Labetalol.
FendilineLabetalol may increase the hypotensive activities of Fendiline.
FenfluramineThe serum concentration of Labetalol can be increased when it is combined with Fenfluramine.
FenoldopamLabetalol may increase the hypotensive activities of Fenoldopam.
FenoprofenFenoprofen may decrease the antihypertensive activities of Labetalol.
FenoterolThe risk or severity of adverse effects can be increased when Labetalol is combined with Fenoterol.
FenthionFenthion may increase the bradycardic activities of Labetalol.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Labetalol.
FingolimodLabetalol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Labetalol.
FlunarizineLabetalol may increase the hypotensive activities of Flunarizine.
FlunixinFlunixin may decrease the antihypertensive activities of Labetalol.
FluoxetineThe serum concentration of Labetalol can be increased when it is combined with Fluoxetine.
FluphenazineFluphenazine may increase the hypotensive activities of Labetalol.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Labetalol.
FluvoxamineThe metabolism of Labetalol can be decreased when combined with Fluvoxamine.
FosinoprilFosinopril may increase the hypotensive activities of Labetalol.
FurazolidoneFurazolidone may increase the hypotensive activities of Labetalol.
FurosemideThe risk or severity of adverse effects can be increased when Labetalol is combined with Furosemide.
GabapentinLabetalol may increase the hypotensive activities of Gabapentin.
GalantamineGalantamine may increase the bradycardic activities of Labetalol.
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Labetalol.
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Labetalol.
GlibornurideLabetalol may increase the hypoglycemic activities of Glibornuride.
GliclazideLabetalol may increase the hypoglycemic activities of Gliclazide.
GlimepirideLabetalol may increase the hypoglycemic activities of Glimepiride.
GlipizideLabetalol may increase the hypoglycemic activities of Glipizide.
GliquidoneLabetalol may increase the hypoglycemic activities of Gliquidone.
GlisoxepideLabetalol may increase the hypoglycemic activities of Glisoxepide.
GlyburideLabetalol may increase the hypoglycemic activities of Glyburide.
GTS-21The risk or severity of adverse effects can be increased when Labetalol is combined with GTS-21.
GuanabenzLabetalol may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Labetalol.
GuanethidineLabetalol may increase the hypotensive activities of Guanethidine.
GuanfacineLabetalol may increase the hypotensive activities of Guanfacine.
HaloperidolThe metabolism of Labetalol can be decreased when combined with Haloperidol.
HexamethoniumLabetalol may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Labetalol.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Labetalol.
Huperzine AHuperzine A may increase the bradycardic activities of Labetalol.
HydracarbazineHydracarbazine may increase the hypotensive activities of Labetalol.
HydralazineLabetalol may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideLabetalol may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideLabetalol may increase the hypotensive activities of Hydroflumethiazide.
Hydroxyamphetamine hydrobromideThe risk or severity of adverse effects can be increased when Labetalol is combined with Hydroxyamphetamine hydrobromide.
HydroxychloroquineThe metabolism of Labetalol can be decreased when combined with Hydroxychloroquine.
IbuprofenIbuprofen may decrease the antihypertensive activities of Labetalol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Labetalol.
IcatibantIcatibant may decrease the antihypertensive activities of Labetalol.
IloprostIloprost may increase the hypotensive activities of Labetalol.
ImipramineThe metabolism of Labetalol can be decreased when combined with Imipramine.
IndalpineThe serum concentration of Labetalol can be increased when it is combined with Indalpine.
IndapamideLabetalol may increase the hypotensive activities of Indapamide.
IndenololLabetalol may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Labetalol can be decreased when combined with Indinavir.
IndomethacinIndomethacin may decrease the antihypertensive activities of Labetalol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Labetalol.
IndoraminLabetalol may increase the antihypertensive activities of Indoramin.
Insulin PorkLabetalol may increase the hypoglycemic activities of Insulin Pork.
IproclozideIproclozide may increase the hypotensive activities of Labetalol.
IproniazidIproniazid may increase the hypotensive activities of Labetalol.
IrbesartanLabetalol may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Labetalol.
IsoflurophateIsoflurophate may increase the bradycardic activities of Labetalol.
IsoniazidThe metabolism of Labetalol can be decreased when combined with Isoniazid.
IsoprenalineThe risk or severity of adverse effects can be increased when Labetalol is combined with Isoprenaline.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Labetalol is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Labetalol is combined with Isosorbide Mononitrate.
IsoxicamIsoxicam may decrease the antihypertensive activities of Labetalol.
IsoxsuprineThe risk or severity of adverse effects can be increased when Labetalol is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Labetalol.
IvabradineLabetalol may increase the bradycardic activities of Ivabradine.
KebuzoneKebuzone may decrease the antihypertensive activities of Labetalol.
KetoconazoleThe metabolism of Labetalol can be decreased when combined with Ketoconazole.
KetoprofenKetoprofen may decrease the antihypertensive activities of Labetalol.
KetorolacKetorolac may decrease the antihypertensive activities of Labetalol.
LacidipineLabetalol may increase the hypotensive activities of Lacidipine.
LacosamideLabetalol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LamotrigineLabetalol may increase the hypotensive activities of Lamotrigine.
LanreotideLabetalol may increase the bradycardic activities of Lanreotide.
LatanoprostLabetalol may increase the hypotensive activities of Latanoprost.
LeflunomideLeflunomide may decrease the antihypertensive activities of Labetalol.
LercanidipineLercanidipine may increase the hypotensive activities of Labetalol.
LevobunololThe risk or severity of adverse effects can be increased when Labetalol is combined with Levobunolol.
LevodopaLabetalol may increase the orthostatic hypotensive activities of Levodopa.
LevomilnacipranThe serum concentration of Labetalol can be increased when it is combined with Levomilnacipran.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Labetalol.
LinezolidLinezolid may increase the hypertensive activities of Labetalol.
LisinoprilLabetalol may increase the hypotensive activities of Lisinopril.
LobelineThe risk or severity of adverse effects can be increased when Labetalol is combined with Lobeline.
LofexidineLabetalol may increase the hypotensive activities of Lofexidine.
LopinavirThe metabolism of Labetalol can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Labetalol can be decreased when combined with Lorcaserin.
LornoxicamLornoxicam may decrease the antihypertensive activities of Labetalol.
LosartanLabetalol may increase the hypotensive activities of Losartan.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Labetalol.
Lu AA21004The serum concentration of Labetalol can be increased when it is combined with Lu AA21004.
LucinactantLabetalol may increase the bradycardic activities of Lucinactant.
LumefantrineThe metabolism of Labetalol can be decreased when combined with Lumefantrine.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Labetalol.
MacitentanLabetalol may increase the hypotensive activities of Macitentan.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Labetalol.
Magnesium SulfateLabetalol may increase the hypotensive activities of Magnesium Sulfate.
MalathionMalathion may increase the bradycardic activities of Labetalol.
ManidipineLabetalol may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Labetalol is combined with Mannitol.
MasoprocolMasoprocol may decrease the antihypertensive activities of Labetalol.
MebanazineMebanazine may increase the hypotensive activities of Labetalol.
MecamylamineLabetalol may increase the hypotensive activities of Mecamylamine.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Labetalol.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Labetalol.
MefloquineMefloquine may increase the bradycardic activities of Labetalol.
MeloxicamMeloxicam may decrease the antihypertensive activities of Labetalol.
MemantineMemantine may increase the bradycardic activities of Labetalol.
MephentermineThe risk or severity of adverse effects can be increased when Labetalol is combined with Mephentermine.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Labetalol.
MesalazineMesalazine may decrease the antihypertensive activities of Labetalol.
MesoridazineMesoridazine may increase the hypotensive activities of Labetalol.
MetamizoleMetamizole may decrease the antihypertensive activities of Labetalol.
MetaraminolThe risk or severity of adverse effects can be increased when Labetalol is combined with Metaraminol.
MethacholineThe risk or severity of adverse effects can be increased when Labetalol is combined with Methacholine.
MethadoneThe metabolism of Labetalol can be decreased when combined with Methadone.
MethamphetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Methamphetamine.
MethazolamideThe risk or severity of adverse effects can be increased when Labetalol is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Labetalol.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Labetalol.
MethoxamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Methoxamine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Labetalol.
MethyldopaLabetalol may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Labetalol.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Labetalol.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Labetalol.
MetipranololLabetalol may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Labetalol.
MetoprololMetoprolol may increase the hypotensive activities of Labetalol.
MibefradilLabetalol may increase the hypotensive activities of Mibefradil.
MidodrineLabetalol may increase the bradycardic activities of Midodrine.
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Labetalol.
MilnacipranThe serum concentration of Labetalol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the bradycardic activities of Labetalol.
MinoxidilMinoxidil may increase the hypotensive activities of Labetalol.
MirabegronThe metabolism of Labetalol can be decreased when combined with Mirabegron.
MoclobemideMoclobemide may increase the hypotensive activities of Labetalol.
MoexiprilLabetalol may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Labetalol.
MoricizineMoricizine may increase the hypotensive activities of Labetalol.
MoxonidineLabetalol may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Labetalol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Labetalol.
NabiloneNabilone may increase the tachycardic activities of Labetalol.
NabumetoneNabumetone may decrease the antihypertensive activities of Labetalol.
NadololLabetalol may increase the hypotensive activities of Nadolol.
NaftifineNaftifine may decrease the antihypertensive activities of Labetalol.
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Labetalol.
NaproxenNaproxen may decrease the antihypertensive activities of Labetalol.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Labetalol.
NebivololLabetalol may increase the hypotensive activities of Nebivolol.
NeostigmineNeostigmine may increase the bradycardic activities of Labetalol.
NepafenacNepafenac may decrease the antihypertensive activities of Labetalol.
NesiritideThe risk or severity of adverse effects can be increased when Labetalol is combined with Nesiritide.
NevirapineThe metabolism of Labetalol can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Labetalol.
NicardipineLabetalol may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Labetalol.
NicotineThe risk or severity of adverse effects can be increased when Labetalol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Labetalol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Labetalol.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Labetalol.
NiguldipineLabetalol may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Labetalol can be decreased when combined with Nilotinib.
NiludipineLabetalol may increase the hypotensive activities of Niludipine.
NilvadipineLabetalol may increase the hypotensive activities of Nilvadipine.
NimesulideNimesulide may decrease the antihypertensive activities of Labetalol.
NimesulideLabetalol may increase the hypotensive activities of Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Labetalol.
NisoldipineNisoldipine may increase the hypotensive activities of Labetalol.
NitrendipineLabetalol may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Labetalol is combined with Nitroglycerin.
NitroprussideNitroprusside may increase the hypotensive activities of Labetalol.
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Labetalol.
NylidrinThe risk or severity of adverse effects can be increased when Labetalol is combined with Nylidrin.
ObinutuzumabLabetalol may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Labetalol.
OctreotideOctreotide may increase the bradycardic activities of Labetalol.
OlanzapineThe serum concentration of Labetalol can be increased when it is combined with Olanzapine.
OlmesartanOlmesartan may increase the hypotensive activities of Labetalol.
OlopatadineOlopatadine may decrease the antihypertensive activities of Labetalol.
OlsalazineOlsalazine may decrease the antihypertensive activities of Labetalol.
OmapatrilatLabetalol may increase the hypotensive activities of Omapatrilat.
OrciprenalineThe risk or severity of adverse effects can be increased when Labetalol is combined with Orciprenaline.
OrgoteinOrgotein may decrease the antihypertensive activities of Labetalol.
OuabainLabetalol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Labetalol.
OxprenololLabetalol may increase the hypotensive activities of Oxprenolol.
OxymetazolineThe risk or severity of adverse effects can be increased when Labetalol is combined with Oxymetazoline.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Labetalol.
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Labetalol.
PanobinostatThe metabolism of Labetalol can be decreased when combined with Panobinostat.
PapaverineThe risk or severity of adverse effects can be increased when Labetalol is combined with Papaverine.
ParecoxibParecoxib may decrease the antihypertensive activities of Labetalol.
PargylineLabetalol may increase the hypotensive activities of Pargyline.
ParoxetineThe serum concentration of Labetalol can be increased when it is combined with Paroxetine.
PasireotideLabetalol may increase the bradycardic activities of Pasireotide.
Peginterferon alfa-2bThe serum concentration of Labetalol can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololLabetalol may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Labetalol.
PentoliniumLabetalol may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Labetalol.
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Labetalol.
PerhexilineLabetalol may increase the hypotensive activities of Perhexiline.
PerindoprilLabetalol may increase the hypotensive activities of Perindopril.
PerphenazinePerphenazine may increase the hypotensive activities of Labetalol.
PhenelzinePhenelzine may increase the hypotensive activities of Labetalol.
PheniprazinePheniprazine may increase the hypotensive activities of Labetalol.
PhenmetrazineThe risk or severity of adverse effects can be increased when Labetalol is combined with Phenmetrazine.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Labetalol.
PhenoxybenzamineLabetalol may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Labetalol.
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Labetalol.
PhentolamineLabetalol may increase the hypotensive activities of Phentolamine.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Labetalol.
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Labetalol.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Labetalol.
PhysostigminePhysostigmine may increase the bradycardic activities of Labetalol.
PilocarpineThe risk or severity of adverse effects can be increased when Labetalol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Labetalol.
PinacidilLabetalol may increase the hypotensive activities of Pinacidil.
PinaveriumLabetalol may increase the hypotensive activities of Pinaverium.
PindololLabetalol may increase the hypotensive activities of Pindolol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Labetalol.
PirlindolePirlindole may increase the hypotensive activities of Labetalol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Labetalol.
PivhydrazinePivhydrazine may increase the hypotensive activities of Labetalol.
PolythiazideLabetalol may increase the hypotensive activities of Polythiazide.
Poractant alfaLabetalol may increase the bradycardic activities of Poractant alfa.
PractololPractolol may increase the orthostatic hypotensive activities of Labetalol.
PrazosinPrazosin may increase the antihypertensive activities of Labetalol.
PregabalinLabetalol may increase the hypotensive activities of Pregabalin.
PrenylamineLabetalol may increase the hypotensive activities of Prenylamine.
PrimaquineThe metabolism of Labetalol can be decreased when combined with Primaquine.
PrimidonePrimidone may increase the hypotensive activities of Labetalol.
ProcaterolThe risk or severity of adverse effects can be increased when Labetalol is combined with Procaterol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Labetalol.
PromazinePromazine may increase the hypotensive activities of Labetalol.
PromethazinePromethazine may increase the hypotensive activities of Labetalol.
PropacetamolPropacetamol may decrease the antihypertensive activities of Labetalol.
PropafenoneThe serum concentration of Labetalol can be increased when it is combined with Propafenone.
PropafenoneLabetalol may increase the bradycardic activities of Propafenone.
PropranololPropranolol may increase the hypotensive activities of Labetalol.
PseudoephedrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Pseudoephedrine.
PTC299PTC299 may decrease the antihypertensive activities of Labetalol.
PyridostigminePyridostigmine may increase the bradycardic activities of Labetalol.
QuetiapineThe risk or severity of adverse effects can be increased when Labetalol is combined with Quetiapine.
QuinaprilLabetalol may increase the hypotensive activities of Quinapril.
QuinidineThe metabolism of Labetalol can be decreased when combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Labetalol.
RacepinephrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Racepinephrine.
RamiprilRamipril may increase the hypotensive activities of Labetalol.
RanolazineThe metabolism of Labetalol can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypotensive activities of Labetalol.
RegorafenibRegorafenib may increase the bradycardic activities of Labetalol.
RemikirenRemikiren may increase the hypotensive activities of Labetalol.
RescinnamineLabetalol may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Labetalol.
ResveratrolResveratrol may decrease the antihypertensive activities of Labetalol.
RiociguatLabetalol may increase the hypotensive activities of Riociguat.
RisedronateLabetalol may increase the hypotensive activities of Risedronate.
RisperidoneLabetalol may increase the hypotensive activities of Risperidone.
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Labetalol.
RitodrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Ritodrine.
RitonavirThe metabolism of Labetalol can be decreased when combined with Ritonavir.
RituximabLabetalol may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Labetalol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Labetalol.
RolapitantThe metabolism of Labetalol can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Labetalol can be decreased when combined with Ropinirole.
RuxolitinibRuxolitinib may increase the bradycardic activities of Labetalol.
SafrazineSafrazine may increase the hypotensive activities of Labetalol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Labetalol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Labetalol.
SalsalateSalsalate may decrease the antihypertensive activities of Labetalol.
SaprisartanLabetalol may increase the hypotensive activities of Saprisartan.
SecobarbitalSecobarbital may increase the hypotensive activities of Labetalol.
SelegilineSelegiline may increase the hypotensive activities of Labetalol.
SelexipagLabetalol may increase the hypotensive activities of Selexipag.
SeratrodastSeratrodast may decrease the antihypertensive activities of Labetalol.
SertralineThe serum concentration of Labetalol can be increased when it is combined with Sertraline.
SildenafilSildenafil may increase the antihypertensive activities of Labetalol.
SilodosinLabetalol may increase the antihypertensive activities of Silodosin.
SitaxentanLabetalol may increase the hypotensive activities of Sitaxentan.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Labetalol.
SpiraprilLabetalol may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Labetalol.
SRT501SRT501 may decrease the antihypertensive activities of Labetalol.
StiripentolThe metabolism of Labetalol can be decreased when combined with Stiripentol.
SufentanilLabetalol may increase the bradycardic activities of Sufentanil.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Labetalol.
SulindacSulindac may decrease the antihypertensive activities of Labetalol.
SuprofenSuprofen may decrease the antihypertensive activities of Labetalol.
SynephrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Synephrine.
TacrineTacrine may increase the bradycardic activities of Labetalol.
TadalafilTadalafil may increase the antihypertensive activities of Labetalol.
TamsulosinLabetalol may increase the antihypertensive activities of Tamsulosin.
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Labetalol.
TelmisartanLabetalol may increase the hypotensive activities of Telmisartan.
TemocaprilLabetalol may increase the hypotensive activities of Temocapril.
TenoxicamTenoxicam may decrease the antihypertensive activities of Labetalol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Labetalol.
TerazosinLabetalol may increase the antihypertensive activities of Terazosin.
TerbinafineThe metabolism of Labetalol can be decreased when combined with Terbinafine.
TerbutalineThe risk or severity of adverse effects can be increased when Labetalol is combined with Terbutaline.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Labetalol.
TerlipressinLabetalol may increase the hypotensive activities of Terlipressin.
TetryzolineThe risk or severity of adverse effects can be increased when Labetalol is combined with Tetryzoline.
ThiamylalThiamylal may increase the hypotensive activities of Labetalol.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Labetalol.
ThiopentalThiopental may increase the hypotensive activities of Labetalol.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Labetalol.
ThioridazineThioridazine may increase the hypotensive activities of Labetalol.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Labetalol.
TiboloneLabetalol may increase the hypotensive activities of Tibolone.
TiclopidineThe metabolism of Labetalol can be decreased when combined with Ticlopidine.
TicrynafenLabetalol may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Labetalol.
TipranavirThe metabolism of Labetalol can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Labetalol is combined with Tizanidine.
TofacitinibTofacitinib may increase the bradycardic activities of Labetalol.
TolazamideLabetalol may increase the hypoglycemic activities of Tolazamide.
TolazolineLabetalol may increase the hypotensive activities of Tolazoline.
TolbutamideLabetalol may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Labetalol.
Tolfenamic AcidLabetalol may increase the hypotensive activities of Tolfenamic Acid.
TolmetinTolmetin may decrease the antihypertensive activities of Labetalol.
ToloxatoneToloxatone may increase the hypotensive activities of Labetalol.
TorasemideTorasemide may increase the hypotensive activities of Labetalol.
TrandolaprilTrandolapril may increase the hypotensive activities of Labetalol.
TranilastTranilast may decrease the antihypertensive activities of Labetalol.
TranilastLabetalol may increase the hypotensive activities of Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Labetalol.
TranylcypromineTranylcypromine may increase the hypotensive activities of Labetalol.
TravoprostTravoprost may increase the hypotensive activities of Labetalol.
TrazodoneThe serum concentration of Labetalol can be increased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Labetalol.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Labetalol.
TrichlorfonTrichlorfon may increase the bradycardic activities of Labetalol.
TrichlormethiazideLabetalol may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Labetalol.
TriflupromazineTriflupromazine may increase the hypotensive activities of Labetalol.
TrimazosinLabetalol may increase the antihypertensive activities of Trimazosin.
TrimethaphanLabetalol may increase the hypotensive activities of Trimethaphan.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Labetalol.
TubocurarineTubocurarine may increase the bradycardic activities of Labetalol.
TyramineThe risk or severity of adverse effects can be increased when Labetalol is combined with Tyramine.
UdenafilUdenafil may increase the antihypertensive activities of Labetalol.
UnoprostoneLabetalol may increase the hypotensive activities of Unoprostone.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Labetalol.
ValsartanValsartan may increase the hypotensive activities of Labetalol.
VardenafilVardenafil may increase the antihypertensive activities of Labetalol.
VareniclineThe risk or severity of adverse effects can be increased when Labetalol is combined with Varenicline.
VenlafaxineThe metabolism of Labetalol can be decreased when combined with Venlafaxine.
VerapamilLabetalol may increase the hypotensive activities of Verapamil.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Labetalol.
VilazodoneThe serum concentration of Labetalol can be increased when it is combined with Vilazodone.
VortioxetineThe serum concentration of Labetalol can be increased when it is combined with Vortioxetine.
XylometazolineLabetalol may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Labetalol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Labetalol.
ZiconotideLabetalol may increase the hypotensive activities of Ziconotide.
ZileutonZileuton may decrease the antihypertensive activities of Labetalol.
ZimelidineThe serum concentration of Labetalol can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Labetalol can be decreased when combined with Ziprasidone.
ZomepiracZomepirac may decrease the antihypertensive activities of Labetalol.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Riva E, Mennini T, Latini R: The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers. Br J Pharmacol. 1991 Dec;104(4):823-8. [PubMed:1687367 ]
  2. Monopoli A, Bamonte F, Forlani A, Ongini E, Parravicini L: Effects of the R, R-isomer of labetalol, SCH 19927, in isolated tissues and in spontaneously hypertensive rats during a repeated treatment. Arch Int Pharmacodyn Ther. 1984 Dec;272(2):256-63. [PubMed:6151824 ]
  3. Sassard J, Zech PY, Pozet N, Cuisinaud G, Vincent M: [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient]. J Pharmacol. 1983;14 Suppl 2:121-9. [PubMed:6355664 ]
  4. Nakagawa Y, Takeda K, Sakurai H, Mitomi A, Imai S: [Antihypertensive effects of labetalol in three types of hypertensive models of rats (author's transl)]. Nihon Yakurigaku Zasshi. 1981 Apr;77(4):435-45. [PubMed:7286847 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Pujos E, Cren-Olive C, Paisse O, Flament-Waton MM, Grenier-Loustalot MF: Comparison of the analysis of beta-blockers by different techniques. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 1;877(31):4007-14. doi: 10.1016/j.jchromb.2009.10.014. Epub 2009 Oct 17. [PubMed:19879818 ]
  7. Rosendorff C: Beta-blocking agents with vasodilator activity. J Hypertens Suppl. 1993 Jun;11(4):S37-40. [PubMed:8104240 ]
  8. van Zwieten PA: An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993 Apr;45(4):509-17. [PubMed:7684671 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Doggrell SA: The effects of labetalol and dilevalol on isolated cardiovascular preparations of the guinea-pig and rat. J Pharm Pharmacol. 1992 Dec;44(12):1001-6. [PubMed:1361547 ]
  2. Doggrell SA: Relaxant and beta 2-adrenoceptor blocking activities of labetalol, dilevalol, amosulalol and KF-4317 on the rat isolated aorta. J Pharm Pharmacol. 1988 Nov;40(11):812-5. [PubMed:2907566 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  4. Sassard J, Zech PY, Pozet N, Cuisinaud G, Vincent M: [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient]. J Pharmacol. 1983;14 Suppl 2:121-9. [PubMed:6355664 ]
  5. Pujos E, Cren-Olive C, Paisse O, Flament-Waton MM, Grenier-Loustalot MF: Comparison of the analysis of beta-blockers by different techniques. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 1;877(31):4007-14. doi: 10.1016/j.jchromb.2009.10.014. Epub 2009 Oct 17. [PubMed:19879818 ]
  6. Rosendorff C: Beta-blocking agents with vasodilator activity. J Hypertens Suppl. 1993 Jun;11(4):S37-40. [PubMed:8104240 ]
  7. van Zwieten PA: An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993 Apr;45(4):509-17. [PubMed:7684671 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
References
  1. Bernstein JS, Ebert TJ, Stowe DF, Schmeling WT, Nelson MA, Woods MP: Partial attenuation of hemodynamic responses to rapid sequence induction and intubation with labetalol. J Clin Anesth. 1989;1(6):444-51. [PubMed:2696507 ]
  2. Nakamura T, Maruyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T: Tamsulosin: assessment of affinityof (3)H-P razosin binding to two alpha-1- adrenoceptor subtypes in the canine aorta. Pharmacology. 1999 Nov;59(5):234-8. [PubMed:10529655 ]
  3. Sassard J, Zech PY, Pozet N, Cuisinaud G, Vincent M: [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient]. J Pharmacol. 1983;14 Suppl 2:121-9. [PubMed:6355664 ]
  4. Pedersen ME, Cockcroft JR: The vasodilatory beta-blockers. Curr Hypertens Rep. 2007 Aug;9(4):269-77. [PubMed:17686376 ]
  5. Shiraishi K, Moriya M, Miyake N, Takayanagi I: Alpha 1-adrenoceptor blocking activities of bevantolol hydrochloride(NC-1400) and labetalol in rat isolated thoracic aorta--do they distinguish between subtypes? Gen Pharmacol. 1992 Sep;23(5):843-5. [PubMed:1358746 ]
  6. Rosendorff C: Beta-blocking agents with vasodilator activity. J Hypertens Suppl. 1993 Jun;11(4):S37-40. [PubMed:8104240 ]
  7. van Zwieten PA: An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993 Apr;45(4):509-17. [PubMed:7684671 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23